GlassScriptPhysician profile
Candace Lemke
NPI 1043446776
$5,359.95
in general payments reported to CMS, 2019-2025
18 companies · $1,124 in 2025
The $1,124 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $462 · 2022: $1,511 · 2023: $1,558 · 2024: $706 · 2025: $1,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,207 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,207.45 |
| Education | $179.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,062.96 | 2021-2022 | |
| Corium, LLC | $870.13 | 2022-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $533.10 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $504.32 | 2022-2023 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $422.70 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $362.24 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $270.58 | 2023-2025 | Uzedy, Austedo |
| Abbvie INC. | $236.81 | 2023-2025 | |
| Lundbeck LLC | $221.21 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Tris Pharma INC | $195.97 | 2022-2025 | Dyanavel Xr |
| Alkermes, INC. | $179.53 | 2021-2025 | Aristada, Lybalvi |
| Biogen, INC. | $143.72 | 2024 | |
| Indivior INC. | $114.07 | 2022-2025 | Perseris, Sublocade |
| Axsome Therapeutics, INC. | $93.41 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $69.80 | 2022-2025 | Invega Sustenna |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $47.87 | 2023-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $17.66 | 2023 | Trintellix |
| Almatica Pharma LLC | $13.87 | 2023 | Gralise, Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candace Lemke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.